Clinical trials: Herpes Simplex Virus
Herpes Simplex
Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth
The purpose of this study is to test whether long-term treatment with oral acyclovir improves the outcome for infants with herpes simplex virus (HSV) disease of the skin, eyes, and mouth (SEM).
- Trial name
- NCT00031447
- Testing
- Acyclovir
- Where
- 28 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipients
Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients
The purpose of this study is to find out whether Varivax is safe for use in children with kidney transplants and whether it protects children from serious infection.
- Trial name
- NCT00005009
- Testing
- Varivax®
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Herpes Simplex, Genital
Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission
The University of Washington has received funding to conduct a proof-of-concept trial to assess the impact of suppression of genital herpes on HIV infectiousness.
- Conditions
- HIV Infection, Herpes Simplex, Genital, Sexually Transmitted Diseases
- Trial name
- NCT00194519
- Testing
- Generic acyclovir
- Where
- 13 sites in Botswana, Kenya and 5 more
- Volunteers
- 3,408 people
- Sponsor
- University of Washington
Advanced Solid Tumor, Sarcoma
A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors
A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer
- Trial name
- NCT05602792
- Testing
- T3011
- Where
- 19 sites in China
- Volunteers
- 233 people
- Sponsor
- ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma
OH2 Injection in Solid Tumors
This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma).
- Trial name
- NCT04386967
- Testing
- OH2 injection, Keytruda
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Herpes Genitalis
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
This is a randomized, double-blind, double-dummy study of single dose HDIT101 versus Standard of Care Valaciclovir. HSV-2-positive patients with at least 4 anogenital herpes lesions in the last 12 months (or at least 2 herpes…
- Trial name
- MATCH-2 (NCT04165122)
- Testing
- HDIT101, Valaciclovir
- Where
- 8 sites in Germany
- Volunteers
- 122 people
- Sponsor
- Heidelberg ImmunoTherapeutics GmbH
Postherpetic Neuralgia
Erector Spinae Plane Block in Post-herpetic Neuralgia
This randomized clinical study will be carried out on 72 patients admitted to the pain clinic in Tanta University Hospitals with post-herpetic neuralgia.
- Trial name
- NCT04546334
- Testing
- Medical treatment, Real Erector Spinae block, Real Erector Spinae block with magnesium sulphate
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Tanta University
Malignant Glioma of Brain, Glioblastoma
ADV-TK Improves Outcome of Recurrent High-Grade Glioma
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and…
- Trial name
- HGG-01 (NCT00870181)
- Testing
- ADV-TK/GCV, Surgery, systemic chemotherapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Huazhong University of Science and Technology
Herpes Labialis
Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis
The aim of this study is to determine the safety and efficacy of a topical natural health product in comparison to placebo for the treatment of herpes labialis.
- Trial name
- NCT02582086
- Testing
- BOR15001L7
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Laboratoire Boreaderme Inc.
Oral Herpes Simplex
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection
The purpose of this study is to determine if a new treatment is effective for the treatment of recurrent symptomatic oral herpes virus infections.
- Trial name
- NCT01308424
- Testing
- BTL TML HSV
- Where
- 4 sites in United States
- Volunteers
- 171 people
- Sponsor
- Beech Tree Labs, Inc.
Recurrent Herpes Labialis
Place Controlled Study to Treat Recurrent Herpes Labialis.
About 80% of the worldwide population is positive on HSV antibodies. In the United States the lifetime prevalence of recurrent herpes labialis is estimated at 20% to 40%, with approximately 100 million episodes occurring in the…
- Trial name
- NCT00914745
- Testing
- Ointment
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Neonatal Herpes Simplex Infection
Valacyclovir in Neonatal Herpes Simplex Virus Disease
This is an open-label, single center, pharmacokinetic (PK) study to assess valacyclovir pharmacokinetics and pharmacodynamics in neonates and compare to the pharmacokinetics and pharmacodynamics of the standard of care treatment…
- Trial name
- NCT04448392
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Alabama at Birmingham
Herpes Labialis
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
- Trial name
- NCT02265913
- Testing
- Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference)
- Where
- United States
- Volunteers
- 4,076 people
- Sponsor
- Padagis LLC
Urinary Bladder, Overactive, Spinal Cord Injury
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years.
- Trial name
- NCT07227285
- Testing
- Urodynamics, EG110A, Patient-reported Outcome
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cyllene Therapeutics
Herpes Zoster
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem…
- Trial name
- NCT00920218
- Testing
- Herpes Zoster Vaccine 1437173A
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Herper Zoster
Biomarker Study in Patients With Herpes Zoster
Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin)…
- Trial name
- NCT05685797
- Testing
- Herpes zoszter (acute)with inter vention
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Keimyung University Dongsan Medical Center